{
    "id": 3963,
    "name": "thyroid gland carcinoma",
    "source": "DOID",
    "definition": "A thyroid gland cancer that has_material_basis_in epithelial cells. [url:http\\://en.wikipedia.org/wiki/Carcinoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3963",
    "evidence": [
        {
            "id": 885,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Caprelsa (vandetanib) demonstrated efficacy in patients with advanced differentiated thyroid carcinoma (PMID: 22898678).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 576,
                    "pubMedId": 22898678,
                    "title": "Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22898678"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1766,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture (PMID: 17664273).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 589,
                    "pubMedId": 17664273,
                    "title": "Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17664273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1776,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture and in cell line xenograft models (PMID: 23526464).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 312,
                    "pubMedId": 23526464,
                    "title": "Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23526464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1777,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased proliferation of thyroid carcinoma cells harboring a RET M918T mutation in culture (PMID: 23526464).",
            "molecularProfile": {
                "id": 3055,
                "profileName": "RET M918T"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 312,
                    "pubMedId": 23526464,
                    "title": "Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23526464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1779,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited phosphorylation of RET C634W and decreased tumor growth in xenograft models of a human thyroid carcinoma cell line harboring RET C634W mutation (PMID: 23705946).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2039,
                    "pubMedId": 23705946,
                    "title": "In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23705946"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3243,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited proliferation of thyroid carcinoma cells harboring CCDC6-RET (also referred to as RET-PTC1) in culture (PMID: 23526464).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 312,
                    "pubMedId": 23526464,
                    "title": "Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23526464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4420,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Obatoclax induced cell death in human thyroid carcinoma cell lines culture (PMID: 26198850).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 834,
                "therapyName": "Obatoclax",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4530,
                    "pubMedId": 26198850,
                    "title": "Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26198850"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10439,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case report, Nexavar (sorafenib) therapy based on in vitro efficacy testing using patient-derived tumor cells resulted in 43 months of disease-free in a patient with anaplastic thyroid carcinoma (PMID: 27379749).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8451,
                    "pubMedId": 27379749,
                    "title": "Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-Case report of long-term remission and review of literature.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27379749"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10440,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN8054 inhibited growth of tumor cells derived from a patient with anaplastic thyroid carcinoma (PMID: 27379749).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2333,
                "therapyName": "MLN8054",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8451,
                    "pubMedId": 27379749,
                    "title": "Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-Case report of long-term remission and review of literature.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27379749"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10812,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated tumor regression when treated with the triple combination, Tafinlar (dabrafenib), Mekinist (trametinib), and Afinitor (everolimus) (PMID: 27797976).",
            "molecularProfile": {
                "id": 26356,
                "profileName": "BRAF V600E PIK3CA H1047R"
            },
            "therapy": {
                "id": 5650,
                "therapyName": "Dabrafenib + Everolimus + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8849,
                    "pubMedId": 27797976,
                    "title": "Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797976"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10814,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976).",
            "molecularProfile": {
                "id": 26356,
                "profileName": "BRAF V600E PIK3CA H1047R"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8849,
                    "pubMedId": 27797976,
                    "title": "Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797976"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10815,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976).",
            "molecularProfile": {
                "id": 26356,
                "profileName": "BRAF V600E PIK3CA H1047R"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8849,
                    "pubMedId": 27797976,
                    "title": "Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797976"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16260,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 9% (2/22) of patients with CD274 (PD-L1)-positive (1% or more) papillary (n=15) or follicular (n=7) thyroid carcinoma, with a median progression-free survival of 7?months (PMID: 30832606; NCT02054806).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14398,
                    "pubMedId": 30832606,
                    "title": "Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30832606"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01208051",
            "title": "Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2437,
                    "therapyName": "Cediranib + Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 1001,
                    "therapyName": "Cediranib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01655719",
            "title": "Pioglitazone in Thyroid Cancers",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3125,
                    "therapyName": "Pioglitazone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02428712",
            "title": "A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1041,
                    "therapyName": "PLX8394",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02628067",
            "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02834013",
            "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
            "phase": "Phase 0",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03181100",
            "title": "Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                },
                {
                    "id": 4595,
                    "therapyName": "Atezolizumab + Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 3049,
                    "therapyName": "Atezolizumab + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 4825,
                    "therapyName": "Atezolizumab + Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 5606,
                    "therapyName": "Atezolizumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04171622",
            "title": "Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        }
    ]
}